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Ischemic stroke is an acute vascular event that obstructs blood supply to the brain, producing irreversible damage that affects
neurons but also glial and brain vessel cells. Immediately after the stroke, the ischemic tissue produces nitric oxide (NO) to
recover bloodperfusion but also produces superoxide anion.These compounds interact, producing peroxynitrite, which irreversibly
nitrates protein tyrosines.The present studymeasuredNOproduction in a human neuroblastoma (SH-SY5Y), amurine glial (BV2),
a human endothelial cell line (HUVEC), and in primary cultures of human cerebral myocytes (HC-VSMCs) after experimental
ischemia in vitro. Neuronal, endothelial, and inducible NO synthase (NOS) expression was also studied up to 24 h after ischemia,
showing a different time course depending on the NOS type and the cells studied. Finally, we carried out cell viability experiments
on SH-SY5Y cells with H
2
O
2
, a prooxidant agent, and with a NO donor to mimic ischemic conditions. We found that both
compounds were highly toxic when they interacted, producing peroxynitrite. We obtained similar results when all cells were
challenged with peroxynitrite. Our data suggest that peroxynitrite induces cell death and is a very harmful agent in brain
ischemia.
1. Introduction
Ischemic stroke, the most common type of stroke, is an
acute vascular accident caused by blockage in a brain vessel,
which yields to a lack of oxygen supply that dramatically
affects the brain parenchyma and brain vasculature. The
tissue surrounding the ischemic lesionwhere neurons are still
alive, but their viability that is highly compromised, called
the penumbra area, is a major target for ischemic stroke
treatments [1, 2].
After ischemia, nitric oxide (NO) is released by endothe-
lial cells to recover blood perfusion [3]. The NO is pro-
duced by the NO synthases (NOS), a family of enzymes
coded by genes located in different chromosomes [3]. The
major regulator of the vascular tone is the endothelium,
through the endothelial NOS (eNOS). Diffusion of NO
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to vascular smooth myocytes produces myorelaxation in a
cyclic, guanosine monophosphate-dependent manner [4].
The neuronal (nNOS) and inducible (iNOS) enzymes are
expressed in neurons, glial cells, and vascularmyocytes [5–12]
and may contribute to NO production in ischemic processes.
Moreover, a burst of free radicals such as superoxide anion
(O
2
∙−
) [13, 14] is produced after the ischemic event. This
scenario could be very harmful because superoxide anion
has a high affinity for NO, higher than for the superoxide
dismutase [15, 16], and both compounds react with each
other and produce peroxynitrite (ONOO−) [17]. Peroxyni-
trite has a gaseous nature that allows it to spread around
the surrounding tissue to the ischemic focus. Peroxynitrite
provokes protein nitrotyrosination, an irreversible chemical
process consisting in the addition of a nitro group (NO
2
)
to the tyrosine residues to generate 3-nitrotyrosine [18, 19].
This posttranslational modification is pathological because
it usually impairs the physiological function of the proteins
[20, 21]. Evidence of protein nitrotyrosination in ischemic
stroke has been reported [22].
The present study analyzed the role of the different
cell types from brain parenchyma and brain vessels in NO
production. Protein expression and mRNA levels of the
different NOSwere assessed. Moreover, we studied the effects
of peroxynitrite on the viability of the different brain cells.
2. Materials and Methods
2.1. Cell Cultures. Human neuroblastoma cells (SH-SY5Y)
were grown in DMEM (Gibco) supplemented with 15% fetal
bovine serum (FBS; Gibco) and antibiotics (100 units/mL
penicillin and 10−6 𝜇g/mL streptomycin; Gibco). HUVECs
were grown in M-199 medium (Gibco) supplemented with
10% FBS, 3.2mM glutamine (Sigma), and antibiotics. Murine
microglial cells (BV2) were grown in RPMI (Gibco) sup-
plemented with 10% FBS and antibiotics. Primary cultures
of HC-VSMCs were produced from cerebral arteries (basi-
lar) obtained from autopsies of 4 individuals (55.3 ± 5.6
years) and utilized up to the ten passages [23]. Procedure
was approved by the ethics committee of the Institut Mar
d’Investigacio´ Me`dica and the Universitat Pompeu Fabra
(IMIM-IMAS-UPF). Briefly, pieces of tunica media were
incubated with 0.1% collagenase type IV (Sigma) for 35min
at 37∘C and cultured to allow HC-VSMC migration to the
flask surface. Cells were grown inDMEMwith 4.5 g/L glucose
(Sigma), 25mMHEPES (Gibco), 10%FBS, 2.5𝜇g/mL ampho-
tericin B (Gibco), 100 units/mL penicillin, and 10−6 𝜇g/mL
streptomycin.Myocytes were characterized by immunostain-
ing with mouse anti-smooth muscle 𝛼-actin antibody (Ab;
Sigma). Cells were used up to ten passages.
2.2.Mouse EmbryoHippocampal Cell Cultures. Hippocampal
cells were isolated from 18-day-old CB1 mouse embryos.
Procedure was approved by the ethics committee of the
IMIM-IMAS-UPF. Hippocampi were aseptically dissected
and trypsinized. Cells were seeded in DMEM plus 10% horse
serum (Gibco) into 1% poly-L-lysine (Sigma) coated cover-
slips (5 × 104 cells/cover). After 2 h, medium was removed,
and Neurobasal medium containing 1% B27 supplement
(Gibco) plus antibiotics was added. Glial proliferation was
avoided by adding 2 𝜇M cytosine arabinoside (Sigma) at day
3 for 24 h. Cultured hippocampal cells were used for the
experiments on day 7, when they were considered to be
mature neurons [24].
2.3. Human Brain Study. The human cortex sample was
obtained from an autopsy of a patient who had a cortical
ischemic stroke (Servei d’Anatomia Patolo`gica, Hospital del
Mar, Barcelona). The sample was fixed in formalin and
embedded in paraffin. Procedure was approved by the ethics
committee of the Institut Municipal d’Investigacio´ Me`dica
and the Universitat Pompeu Fabra (IMIM-IMAS-UPF).
2.4. In Vitro Ischemia. Ischemia was induced by an oxygen-
glucose deprivation protocol (OGD). Briefly, the culture
medium was replaced with a glucose-free balanced saline
solution containing 116mM NaCl, 5.4mM KCl, 0.8mM
MgSO
4
, 1 mM NaH
2
PO
4
, 26.2mM NaHCO
3
, and 1.8 CaCl
2
,
incubated for 1 h in a nitrogen chamber at 37∘C. The OGD
mediumwas then replaced by culturemedium, and cells were
incubated for up to 12 h or 24 h after OGD under standard
culture conditions.
2.5. Free Radical Production. SH-SY5Y cells were seeded
on 1.5% gelatin-coated 35mm coverslips (1 × 105 cells/well)
for image analysis with a Leica TCS SP confocal micro-
scope. SH-SY5Y cells were seeded in a 96-well plate (1 ×
103 cells/well) for fluorescence quantification with a Fluostar
Optima Microplate Reader (BMG Labtech). In both cases,
cells were subjected to OGD with the OGD medium plus
5 𝜇M2,7-dichlorofluorescin diacetate (DCF-DA; Sigma).The
OGD medium was replaced by culture medium plus 5 𝜇M
DCF-DA, cells were incubated in standard culture condi-
tions, and experimental analysis was completed within 1 h.
2.6. NOAssay. HUVEC, SH-SY5Y, BV2, andHC-VSMC cells
were seeded on T-25 flasks (approximately 5 × 106 cells/flask)
and subjected to OGD. Control media, 12 h post-ischemic
media and 24 h postischemic media were collected, and NO
was measured using a nitrate/nitrite colorimetric assay kit
(Cayman).
2.7. Immunofluorescence. Hippocampal cells (4 × 104 cells/
well) were seeded on 1.5% gelatin coated, 12mm coverslips.
Cells were challenged for 1 h with OGD and maintained
in standard culture conditions up to 24 h. Cells were fixed
and incubated for 2 h at room temperature (RT) with 1 : 500
antinitrotyrosine polyclonal Ab (Chemikon), followed by
incubation with 1 : 500 Alexa Fluor 488 goat anti-rabbit
polyclonal Ab (Dako) for 1 h at RT. Nuclei were stained in
blue with To-pro 3.The human cortex sample was cut at 3 𝜇m,
deparaffinized at 70∘C for 1 h, and washed with decreasing
concentrations of ethanol. Antigen retrieval was performed
with proteinase K at 40𝜇g/mL in a 1 : 1 glycerol and TE
buffer solution. Immunostaining was performed with 1 : 200
mouse monoclonal anti-NTyr Ab (Cayman Chem) for 2 h
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at RT, followed by 1 : 1000 Alexa555-bound anti-mouse as
secondary Ab (Dako) overnight at 4∘C. Sections were stained
with To-pro 3 to identify the nuclei. All the coverslips were
mounted with Mowiol. Images were taken with a Leica TCS
SP confocal microscope and analyzed with Leica confocal
software (Leica).
2.8. Protein Identification by Western Blot. Cell cultures
were lysed on ice with a solution containing 1M Tris-
HCl, 1% Nonidet P-40, 150mM NaCl, 5mM EDTA, 1mM
sodium orthovanadate, 1mM dithiothreitol, pH 7.4, and a
protease inhibitor cocktail (Roche). Protein concentration
was determined by Bio-Rad protein assay. Protein samples
were analyzed using 3–8% Tris-acetate gels (Invitrogen)
for NOS detection. Gels were run at 150V for 1 h and
transferred to nitrocellulose membranes (Millipore) at 100V
for 2 h. Membranes were blocked in Tween 20-Tris buffer
solution (100mM Tris-HCl, 150mM NaCl, and pH 7.5; 0.1%
Tween, 5% milk) and incubated for 2 h at 25∘C with 1 : 1,000
anti-nNOS (Santa Cruz Biotechnology), anti-iNOS (Santa
Cruz Biotech.), and anti-eNOS (Santa Cruz Biotech.) Abs.
Peroxidase-conjugated donkey anti-rabbit and anti-mouse
Abs (Amersham Bioscience) were used as secondary Abs at
1 : 5,000 for 1 h at 25∘C. Bands were visualized with Super
Signal (Pierce) andAmershamBioscienceHyperfilmECLkit.
2.9. RNA Isolation and Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR) Analysis. Total RNA from cell
cultures was isolated using Trizol reagent (Invitrogen),
following the manufacturer instructions. Briefly, 1 𝜇g of
RNA was applied to RT-PCR using the OneStep RT-PCR Kit
(Qiagen,Hamburg, Germany).The iNOS-specific primers for
mice were 5󸀠-CCATCACTGTGTTCCCCC-3󸀠 and 5󸀠-AAG-
GTGGCAGCATCCCC-3󸀠 (Genbank accession number:
NM 010927). The iNOS-specific primers for humans were
5󸀠-CTGCTTGAGGTGGGCGG-3󸀠 and 5󸀠-GTGACTCTGA-
CTCGGGACGCC-3󸀠 (NM 000625). The eNOS-specific
primers were 5󸀠-CAAGTATGCCACCAACCGGG-3󸀠 and 5󸀠-
ACTGAAGGGGGCTGCGG-3󸀠 (NM 000603). The nNOS-
specific primers were 5󸀠-GAGAAGGAGCAGGGGGGG-3󸀠
and 5󸀠-CACATTGGCTGGGTCCCC-3󸀠 (NM 000620).
These primers were used to amplify the different NOS.
Hypoxanthine phosphoribosyltransferase- (hPRT-) specific
primers (5󸀠-GGCCAGACTTTGTTGGATTTG-3󸀠 and 5󸀠-
TGCGCTCATCTTAGGCTTTGT-3󸀠; NM000194) were used
as positive control. Negative control was performed in the
absence of oligonucleotide primers. Results were analyzed
with Image Gauge software (Fuji Photo Film Co.).
2.10. Cell Viability Assay. Cells were seeded in 96-well plates
at a density of 8,000 cells/100𝜇L per well and treated with
3-morpholinosydnonimine hydrochloride (SIN-1), sodium
nitroprussiate (SNP), and/or H
2
O
2
, as described in the corre-
sponding figures. Cells were incubated for 6 or 24 h at 37∘C,
and cell viabilitywasmeasured by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction
method. Absorbances at 540 and 650 nmwere determined in
a Microplate Reader (Bio-Rad) and expressed as percentage
of control.
2.11. Statistical Analysis. Data were expressed as the mean ±
SEM of the values from the number of experiments indicated
in the corresponding figures. Data were analyzed using one-
way ANOVA with Bonferroni post hoc analysis.
3. Results
3.1. Ischemia Induces an Increase in Nitrotyrosination, Reactive
Oxygen Species (ROS), and NO Production in Brain Cells.
A strong labeling for nitrotyrosination was observed in
the cortex from a stroke patient, not only in the brain
parenchyma but also in the tunica intima and media of
the blood vessel (Figure 1(a)). Neurons are very sensitive to
oxidative stress. Therefore, we analyzed the protein nitroty-
rosination after ischemia in mature mouse hippocampal
neurons (Figure 1(b)). We assayed the effect of ischemia
by subjecting the hippocampal neurons to OGD for 1 h,
followed by reoxygenation. Neurons were maintained in a
growth medium containing glucose for 24 h. We observed
that hippocampal neurons subjected to ischemia had high
levels of nitrotyrosination. The presence of nitrotyrosinated
proteins demonstrated the existence of nitro-oxidative stress
resulting from ischemia.
To study free-radical production after ischemia, we
exposed human neuroblastoma cells (SH-SY5Y) to OGD.
After 1 h, SH-SY5Y cells showed a burst in free radical
production, measured by DCF oxidation (Figure 1(c), right)
and visualized by confocal microscopy (Figure 1(c), left).
In addition to neurons, other brain cell types are found
in the ischemic area; all cell types could contribute to the
damage by producing NO. After the ischemic challenge,
microglia and endothelial cells showed an increase in NO
production (Figure 1(d)) that persisted up to 24 h. Endothelial
cells and microglia were the highest NO producers in both
baseline conditions and after ischemia; SH-SY5Y and brain
vascular myocytes had no effect on NO release due to
ischemia (Figure 1(d)).
3.2. Protein and mRNA Levels of NOS Types Are Modified
in Brain Cells after Ischemia. NO production is dependent
on the expression and activity of the different NOS. For
this reason we examined the effect of ischemic insult on
the protein and mRNA levels of nNOS, eNOS, and iNOS. In
SH-SY5Y cells, we studied nNOS (Figure 2(a)). At 24 h after
ischemia, we observed a significant reduction in nNOS pro-
tein (𝑃 < 0.05), but nNOSmRNA levels were not significantly
affected (Figure 3(a)).
The main responsibility for the NO burst occurring after
brain ischemia has classically been attributed to microglial
cells. We studied the behavior of iNOS protein and mRNA
in microglial cells (BV2) challenged with in vitro ischemia
(Figure 2(b)). We found that iNOS is present in non-
stimulated control microglial cells. Moreover, iNOS expres-
sion increased significantly at 12 h after the ischemic chal-
lenge (𝑃 < 0.005).The analysis of iNOSmRNA revealed, once
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Figure 1: In vitro ischemia induces nitro-oxidative stress. (a) A representative image of nitrotyrosination (bottom image, stained in red) and
bright field (top image) in a section of cortex from a stroke brain analyzed by immunohistochemistry. The arrows indicate blood vessels.
(b) Primary hippocampal cells were subjected to in vitro ischemia followed by reperfusion with normal medium for 24 h. Nitrotyrosine (red
staining) was demonstrated by immunostaining. Nuclei are stained in blue with To-pro 3. (c) Human neuroblastoma cells were subjected to
in vitro ischemia reperfused with normal medium for 24 h. Free radical production was detected by DCF fluorescence and quantified. The
mean fluorescence of DCF represents the levels of ROS. Data are mean ± SEM values of 4 independent experiments. ∗𝑃 < 0.05 versus control.
(d) NO production (expressed in picomoles) was measured in neurons, microglia, endothelial, and vascular smooth muscle cells challenged
with in vitro ischemia and later reoxygenated with normal growingmedium containing glucose at 0, 12, and 24 h. Data aremean ± SEM values
of 4 independent experiments. ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001 versus controls at 0 h.
again, a drop in the iNOSmRNA levels at 12 h (𝑃 < 0.05) that
was normalized 24 h after the ischemic insult (Figure 3(b)).
Regarding the expression of eNOS in endothelial cells
(HUVEC), we did not see any significant change in the
protein content after in vitro ischemia (Figure 2(c)), whereas
the mRNA levels are upregulated after the ischemic challenge
(𝑃 < 0.05; Figure 3(c)).
The iNOS and nNOS expression has been reported in
systemic rat vascular smooth muscle cells [25–29]. Neither
iNOS protein nor iNOS mRNA was detected in myocytes
(primary cultures of HC-VSMC) in basal conditions or after
ischemia (data not shown); nNOS protein and mRNA were
clearly identified (Figure 2(d)). nNOS protein is constitu-
tively present in cerebral vascular myocytes. We did not
observe any difference in nNOS (Figure 2(d)) and mRNA
levels (Figure 3(d)) following exposure to OGD medium.
3.3. ONOO− Induces Cell Death. We used a NO donor
(SNP) to demonstrate that NO alone is not toxic to human
neuroblastoma cells at high physiological concentrations
(Figure 4(a)), tested up to 1.5mM SNP (Figure 4(a)). How-
ever, when SNP was applied together with nontoxic concen-
trations of H
2
O
2
(an oxidative stress source when metabo-
lized by cells), we obtained neurotoxicity due to the formation
of ONOO− at 10 (𝑃 < 0.05) and 20 (𝑃 < 0.05 and 𝑃 < 0.005)
𝜇MH
2
O
2
, even with the lowest SNP concentration (0.5mM),
which is closer to the physiological concentrations obtained
in NO burst production.
The ONOO− donor (SIN-1) was assayed at increasing
concentrations in the different cell types (Figure 4(b)). The
threshold to cause cytotoxicity was at 1mMSIN-1 in endothe-
lial cells and neuroblastoma cells. Myocytes and microglial
cells were more susceptible to ONOO−, with the cytotoxicity
threshold at 100 𝜇M SIN-1.
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Figure 2: NO is produced in different cell types by the different NOS types. Cells were challenged with ischemia and iNOS, eNOS, and nNOS
protein levels were studied immediately at time 0, 12, and 24 h after the ischemic challenge. Densitometric analysis of the bands quantified
NOS expression relative to tubulin in all cell types. Data aremean ± SEM values of 6 experiments formicroglia and 3 experiments for neurons,
endothelial cells, and myocytes. ∗𝑃 < 0.05 versus controls at 0 h.
4. Discussion
Stroke generates a cascade of molecular events as a con-
sequence of arrested blood supply [30]. Immediately after
the first minutes of ischemic cerebral damage, the activity
of eNOS becomes elevated in an attempt to improve blood
supply [31]. Our data demonstrate that NO is released after in
vitro ischemia in brain cells. The NO production is activated
up to 24 h after ischemia,mainly in endothelial andmicroglial
cells. At first it might constitute a homeostatic response to
increase blood perfusion, but studies performed in iNOS and
nNOS knockout (KO) mice suggest that the activation of
these two NOS after ischemia is highly harmful to brain cells
[32, 33].
The regulation of NO levels depends on the levels and
expression of the different NOS. The activity of constitutive
NOS (eNOS and nNOS) is regulated by intracellular calcium
that increases in response to ischemic challenge. iNOS is
regulated at the transcriptional level because it lacks the reg-
ulatory arm activated by Ca2+-calmodulin. Its transcription
is activated by various stimuli, including LPS [34, 35].
We found significantly increased protein levels of iNOS
in BV2 cells at 12 h after in vitro ischemia, and baseline
levels were not totally recovered at 24 h. The regulation of
mRNA expression for iNOS (BV2 cells) showed a decrease in
mRNA levels at 12 h after ischemia, which correlateswith high
protein expression.The high production of NO by microglial
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Figure 3: Differential expression of mRNA NOS types occurs in different cell types. Cells were challenged with ischemia, and iNOS, eNOS,
and nNOS mRNA expression were studied immediately at time 0, 12 and 24 h after the ischemic challenge. The expression of mRNA was
assessed by semiquantitative RT-PCR, and bands were quantified by HPRT densitometric analysis in all cell types. Data are mean ± SEM
values of 3 experiments in all cell types. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01 versus controls at 0 h.
cells after an ischemic challenge would be related to the
nonspecific response of these cells to activation, as occurs
with other immune cells [36] before phagocytosis of the
cellular debris produced by postischemia necrosis [37]. This
NO will not contribute to vasodilation but will mostly react
with superoxide anion to form peroxynitrite. The iNOS KO
mice had less neuronal death after ischemic stroke [32].
Postischemic protein levels (eNOS in HUVECs and
nNOS in SH-SY5Y and HC-VSMCs) had not changed at
24 h. The eNOS mRNA was overexpressed at 12 h, which
strongly suggests an inhibitory translational control of eNOS
expression after ischemia. In one study, neuronal death
increased in eNOS KO mice after a stroke [38], suggesting
a protective role for this enzyme that is likely due to its
direct control of blood flow.On the other hand, nNOSmRNA
levels in SH-SY5Y and HC-VSMCs did not change during
postischemic observation.
Oxidative stress plays a key role in ischemic-reperfusion
situations [13] because mitochondrial dysfunction leads to
a burst in free radical production that cannot be scavenged
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Figure 4: ONOO− induces cell death. (a) Human neuroblastoma cells were treated with increasing concentrations of a NO donor (SNP) and
H
2
O
2
(free radical source). Cells were incubated for 6 h, and cell viability was assayed by MTT reduction. Data are expressed as percentage
of control cells. Data are mean ± SEM values of 7 experiments. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01 versus controls without SNP. (b) Cells were challenged
with increasing concentrations of the ONOO− donor SIN-1, and cell viability was assayed by MTT reduction.
by the constitutive antioxidant cellular defense systems [39].
The large amount of free radicals produced during ischemia
not only scavenges NO but also transforms it into the toxic
ONOO− [17], which yields to the protein nitrotyrosination
and cell death observed in the present study. Although
ONOO− is a short lived molecule [40], its ability to diffuse
through biological membranes can spread its harmful effects
into neighboring cells and tissues.This critical process defines
survival or death in the penumbra area. Consequently, we
analyzed the effects of NO, H
2
O
2
, and NO plus H
2
O
2
on
neuronal survival. Neurotoxicity was only inducedwhen cells
were challenged with NO plus H
2
O
2
, which will produce
peroxynitrite. Furthermore, we assayed increasing concen-
trations of a peroxynitrite donor, SIN-1, on all the brain cell
types. We found a similar pattern of cell viability for all
the cell types at low micromolar concentrations but a major
cytotoxicity for glial cells andHC-VSMCs at 1mMSIN-1.This
effect may be related to a lower antioxidant defense. Further
work is needed to investigate the possible protective role of
antioxidants in the prevention of ischemic damage [41].
5. Conclusion
Our work demonstrates that brain ischemia induces nitro-
oxidative stress that produces protein nitrotyrosination. The
high production of peroxynitrite after ischemia will cause
neuronal death and dramatically affect the survival of other
brain cells.
Nonstandard Abbreviations Used
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BSA: Bovine serum albumin
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eNOS: Endothelial nitric oxide synthase
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iNOS: Inducible nitric oxide synthase
MTT: 3-(4,5-Dimethylthiazol-2-yl)2,5-
diphenyltetrazolium
bromide
NO: Nitric oxide
NOS: Nitric oxide synthase
O
2
−: Superoxide anion
OGD: Oxygen-glucose deprivation
ONOO−: Peroxynitrite anion
RT: Room temperature
RT-PCR: Reverse transcriptase-polymerase chain
reaction
SH-SY5Y: Human neuroblastoma cells
SIN-1: 3-Morpholinosydnonimine
hydrochloride.
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